Cardiovascular adverse effects include a transient increase in cardiac troponin I (cTnI) levels, transient systemic arterial hypertension, and electrocardiographic changes such as sinus tachycardia, sinus bradycardia, and ventricular arrhythmias [1,2,3,12,13,14,17,18]. This evidence concerns the gene TNNI3 and Ventricular arrhythmia.